Request Discount

Immunotherapy Drugs Market (Product - Monoclonal Antibodies, Checkpoint Inhibitors, Vaccines, Inferon’s, and Others; Disease Type - Cancer, Infectious Disease, Autoimmune Disease, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2028

  • Published : May, 2022

  • Rep Id : HC0079

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on the immunotherapy drugs market provides an in-depth analysis of segments and sub-segments in the global as well as regional immunotherapy drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional immunotherapy drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecasts, and dollar values of the global immunotherapy drugs market. According to the report, the global immunotherapy drugs market is projected to grow at a CAGR of 10.5% over the forecast period of 2022-2028.

 

Market Insight

The revenue generated by the immunotherapy drugs market was approximately USD 209 billion in 2022 and is expected to reach approximately USD 380 billion in 2028. and is expected to grow with a CAGR of more than 10.5% by 2028. Immunotherapy is a biological therapy, which harnesses the ability of the immune system of a human body for combating a disease or an infection. Immunotherapy techniques either involve stimulation of the immune system to work smarter against the attack of cancer cells or induction of artificial immune system proteins or some other immune system components to improve immunity. Immunotherapy is an alternative treatment for multiple types of cancers such as brain, bladder, breast, cervical, colorectal, gastric, kidney, lymphoma, leukemia, lung, ovarian, prostate, and melanoma. In the case of cancer, immunotherapy helps in slowing or stopping the cancer cells' growth, stops the spreading of cancer to other regions of the body, and stimulates the immune system to destroy the cancer cells effectively.

 

The COVID-19 pandemic did not appear to have an impact on regular immunotherapy drug prescription and distribution practices. Telemedicine was really popular. There were no modifications in supportive treatments, however, some doctors chose to postpone procedures (if it was part of the patients' treatment plan). Despite the fact that demand was mostly unaffected by the covid-19 epidemic, supply chain interruptions hampered medicine supply and caused delays in the manufacturing of the drugs. During the early months of the pandemic, several institutions postponed non-urgent screening checks. There were also delays in the development of new medications. As the world recovers from the pandemic, the market benefits.

 

The global immunotherapy drugs market is driven by an increasing number of patients with lifestyle-related illnesses and a preference for targeted therapies, which cause minimal side effects. Immunotherapy is gaining importance as an alternative frontline treatment for cancer patients, who are averse to the serious side effects related to chemotherapy. An increasing number of cancer patients, minimal side effects, and increasing awareness among patients are the major factors that are expected to drive the growth of the global immunotherapy drugs market during the forecast period. The combination of an immune checkpoint inhibitor with the common cold virus has led to a better immune response among some advanced melanoma patients. The undergoing research programs related to immunotherapy are expected to yield new drugs and effective treatments for multiple sclerosis, mesothelioma, paralysis, and other diseases during the forecast period. The high cost involved in the manufacturing of immunotherapy drugs is a major challenge for the major players in the market. The high cost of the immunotherapy treatment and high depreciation related to the product cycle are the major restraints to the growth of the global immunotherapy drugs market. Emerging markets are expected to provide opportunities for major players in the global immunotherapy drugs market to expand, due to the increasing demand for alternatives to conventional cancer treatments that are very costly.

 

Geographically, North America is expected to be the dominating region in the market over the forecast period. Asia-Pacific is expected to be the fastest-growing region in the market. The North American region is the largest immunotherapy drugs market in the world. An increasing number of patients with autoimmune diseases, infectious diseases and cancer drive the demand for immunotherapy drugs, as reimbursement plans and insurance make various therapies affordable for them and it drives the growth of the North-American immunotherapy drugs market. The growing number of autoimmune disease and cancer patients drives the growth of the European immunotherapy drugs market. Efficient research & development for developing new drugs and the acceptance of biosimilar immunotherapy drugs are expected to drive the growth of the European immunotherapy drugs market during the forecast period. The presence of a large population, an increasing number of people with lifestyle-related illnesses, and the increasing demand for treatments with minimal side effects in countries such as China, India, Indonesia, and other countries are expected to propel the Asia-Pacific region as the fastest-growing immunotherapy drugs market.


Immunotherapy Drugs Market

 

Segment Covered

The report on the global immunotherapy drugs market covers segments such as product and disease type. On the basis of product, the sub-markets include monoclonal antibodies, checkpoint inhibitors, vaccines, inferon’s, and others. On the basis of disease type, the sub-markets include cancer, infectious disease, autoimmune disease, and others.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Amgen Inc, GlaxoSmithKline PLC, F.Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb, Galena Biopharma, and Inovio Pharmaceuticals.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the immunotherapy drugs market. Moreover, the study highlights current market trends and provides forecasts for 2022-2028. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount